Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
66,577,393
-
Total 13F shares
-
4,923,525
-
Share change
-
+4,923,525
-
Total reported value
-
$24,668,025
-
Price per share
-
$5.01
-
Number of holders
-
23
-
Value change
-
+$24,668,026
-
Number of buys
-
23
Institutional Holders of Cardiff Oncology, Inc. - Common Stock (CRDF) as of Q2 2020
As of 30 Jun 2020,
Cardiff Oncology, Inc. - Common Stock (CRDF) was held by
23 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
4,923,525 shares.
The largest 10 holders included
CAXTON CORP, Avoro Capital Advisors LLC, Opaleye Management Inc., ACUTA CAPITAL PARTNERS, LLC, VANGUARD GROUP INC, RENAISSANCE TECHNOLOGIES LLC, Corriente Advisors, LLC, MERCER GLOBAL ADVISORS INC /ADV, EAM Investors, LLC, and Prospera Financial Services Inc.
This page lists
23
institutional shareholders reporting positions in this security
for the Q2 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.